Three-year outcome analysis of alpha 1-blocker naftopidil for patients with benign prostatic hyperplasia in a prospective multicenter study in Japan

PURPOSE: Our aim was to prospectively analyze the 3-year outcomes of naftopidil treatment for patients with benign prostatic hyperplasia (BPH), including those who dropped out during follow-up and had retreatment for BPH after termination of the drug within 3 years. PATIENTS AND METHODS: Naftopidil,...

Descripción completa

Detalles Bibliográficos
Autores principales: Masumori, Naoya, Tsukamoto, Taiji, Shibuya, Akihiko, Miyao, Noriomi, Kunishima, Yasuharu, Iwasawa, Akihiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4966686/
https://www.ncbi.nlm.nih.gov/pubmed/27524886
http://dx.doi.org/10.2147/PPA.S110440

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4966686/
https://www.ncbi.nlm.nih.gov/pubmed/27524886
http://dx.doi.org/10.2147/PPA.S110440

Ejemplares similares